Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
2.8×-5.6×
Viatris logo
ViatrisVTRS
1.6×-0.1×
Opko Health logo
Opko HealthOPK
3.6×+1.1×
AptarGroup logo
AptarGroupATR
1.7×+0.4×
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
4.9×-6.1×

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×

Where this comes from

Calculated from Amphastar Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's current ratio?
Amphastar Pharmaceuticals (AMPH) reported current ratio of 3.9× in Q1 2026.
How has Amphastar Pharmaceuticals's current ratio changed year-over-year?
Amphastar Pharmaceuticals's current ratio increased by 30.4% year-over-year, from 3× to 3.9×.
What is the long-term trend for Amphastar Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's current ratio has grown at a 10.0% compound annual growth rate (CAGR), from 2.5× to 4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.